After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed Infanrix (GlaxoSmithKline ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...

Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID-19 meant that public awareness around vaccination and its importance in ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...